
US Launches Investigation into Germany Over Pharmaceutical Pricing
The US has launched a Section 301 investigation into Germany concerning alleged underpayment for innovative pharmaceuticals, potentially impacting US commerce. Germany's proposed healthcare reforms and fast-tracking of legislation to reduce drug spending are key concerns.















